Neuromyelitis optica spectrum disorder

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
星期四, 三月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Noetik Appoints Dr. Shafique Virani as Chief Business Officer

Retrieved on: 
星期三, 三月 27, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Recursion, Neuromyelitis optica spectrum disorder, University, Drug discovery, Patient, Cancer, Medicine, Doctor of Philosophy, Bayer, Therapy, COA, Machine learning, CSO, Multimedia, Pharmaceutical industry

Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.

Key Points: 
  • Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240327236059/en/
    "We are thrilled to welcome Shaf to our team as Chief Business Officer.
  • Prior to joining Noetik, Dr. Virani served as Recursion’s Chief Corporate Development Officer, as well as the interim Chief Medical Officer as part of his tenure.
  • As Chief Business Officer, Dr. Virani will accelerate Noetik’s mission through both business development and portfolio strategy by identifying and facilitating strategically impactful transactions.

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期四, 十一月 9, 2023
MFDS, European Economic Area, Result, AIM, Conversation, Research, Bank statement, Financial condition report, ALS, Neuromyelitis optica spectrum disorder, Marketing, Analysis, EEA, NMOSD, Patient, TSX, General Administration of Press and Publication, Cryptocurrency, Clothing, Rare-earth element, Aeterna

TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended September 30, 2023.

Key Points: 
  • - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025
    TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended September 30, 2023.
  • Dollars
    The Company had $38.8 million in cash and cash equivalents at September 30, 2023.
  • Our total revenue for the nine-month period ended September 30, 2023, was $4.4 million as compared to $3.2 million for the same period in 2022, representing an increase of $1.2 million.
  • For reference, the Company’s Management's Discussion and Analysis of Financial Condition and Results of Operations for the third quarter 2023, as well as the Company's unaudited consolidated interim financial statements as of September 30, 2023, will be available on the Company's website ( www.zentaris.com ) in the Investors section or at the Company's profile at www.sedarplus.com and www.sec.gov .

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Retrieved on: 
星期一, 十月 23, 2023
Knowledge, FDA, MedImmune, Policy, Horizon, LAM, Liver transplantation, Drug, Acquisition, Integris Health, Lymphangioleiomyomatosis, FACS, Pfizer, Neuromyelitis optica spectrum disorder, Horizon Therapeutics, University, Therapy, Patient, Transplant, Pharmaceutical industry, Dentistry, Eledone

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.

Key Points: 
  • IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.
  • “We are pleased to welcome Dr. Katz to the Eledon team,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer.
  • “Dr.
  • Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs.

The MOG Project, Pediatric Neurologist Secure CDC Approval to Adopt ICD-10 Code for Rare Disease MOGAD

Retrieved on: 
星期一, 十月 2, 2023
Insurance, Optic neuritis, General assembly, Disease, United Nations, Glycoprotein, CHLA, Neuroimmunology, ICD, Lou Ruvo Center for Brain Health, Knowledge Organization (journal), United Nations General Assembly, Centers for Disease Control and Prevention, Research, Brain, Children's Hospital, Multiple sclerosis, CDC, MOGAD, MD, Patient, Physician, Children's Hospital Los Angeles, Immune system, Optic nerve, Stockholm Environment Institute US Center, Transverse myelitis, Diagnosis, Knowledge, Neuromyelitis optica spectrum disorder, Barrow Neurological Institute, International Classification of Diseases, Video game–related health problems, FDA, Acute disseminated encephalomyelitis, WHO, World Health Organization, Medical device

OLNEY, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- The MOG Project, a nonprofit organization committed to supporting the research and treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) announced that its Executive Director Julia Lefelar, with support from The MOG Project Executive Board and Children's Hospital Los Angeles (CHLA) Pediatric Neurologist Jonathan Santoro, MD, secured approval to have the US Centers for Disease Control and Prevention (CDC) create an ICD-10 code for MOGAD. As of October 1, 2023, an official code for MOGAD is included in the 10th edition of the International Classification of Diseases (ICD) and Related Health Problems, which is relied upon by physicians and insurance providers to classify diagnoses and advise treatment.

Key Points: 
  • Without a CDC code, MOGAD patients had previously been grouped in with patients with similar diseases like neuromyelitis optica spectrum disorder, optic neuritis, acute disseminated encephalomyelitis, transverse myelitis and even multiple sclerosis.
  • "For the MOGAD community, this CDC code is more than a win for better health outcomes and fewer insurance delays, it gives our rare disease an identity and legitimizes it."
  • "The addition of a MOGAD specific ICD-10 code allows patients to better access the therapies that they need to treat their disease," said Santoro.
  • "Further, it allows for disease monitoring across the country, which will increase knowledge and research on this rare neuroimmunology disorder."

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

Retrieved on: 
星期一, 十月 2, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sclerosis, Abstract, Cerebrospinal fluid, Use, Safety, Pregnancy, COVID-19, Clinical trial, Utility, Woman, PIRA, NMOSD, COMPASS, Biomarker, Multiple sclerosis, Ocrelizumab, MS, MRI, Patient, Phases of clinical research, Infant, Neuromyelitis optica spectrum disorder, Phase, Flour, Pharmaceutical industry, Frankincense, Dietary supplement, Medical imaging

Regular abstracts available from October 01, 2023 at 8:00 CEST.

Key Points: 
  • Regular abstracts available from October 01, 2023 at 8:00 CEST.
  • *Late-breaking abstracts available from October 11, 2023 at 8:00 CEST.
  • Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the Phase III OCARINA II study
    Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the Phase Ib dose-finding OCARINA I study
    The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies
    Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
    October 13 (Scientific Session 20: Female health)
    Ocrelizumab dose selection for treatment of paediatric relapsing-remitting multiple sclerosis: preliminary pharmacokinetic, safety and efficacy results from the OPERETTA 1 study
    Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis: analysis of the largest available outcome database
    Combining measures from clinical assessments, imaging and fluid biomarkers at one year to predict MS progression at two years
    Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study
    Utility and implementation of a federated research infrastructure to assess lack disease stability as a real-world surrogate of PIRA, by combining MS clinical trial and real-world cohort data (the INTONATE MS consortium)
    Specific unmet medical needs in the care of patients with relapsing multiple sclerosis: final results from the PROFILE RMS study
    Ocrelizumab safety under real-world conditions: Contrasting investigator-reported safety with patient-reported safety in people with multiple sclerosis (CONFIDENCE, COMPASS and TrotzMS)
    Implications of progression independent of relapse activity (PIRA) for multiple sclerosis clinical trials: item banks could provide the precise patient-reported outcome measures needed
    Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: results from the Phase II FENopta study
    October 13 (Scientific Session 22: Late Breaking Abstracts*)
    Fenebrutinib, a noncovalent, reversible, Bruton's tyrosine kinase inhibitor, potently blocks neuroinflammation induced by Fcy receptor activation in human microglial systems: implications for multiple sclerosis treatment
    Long-term efficacy of satralizumab in patients with AQP4-IgG+ NMOSD: updated analysis from the open-label SAkuraMoon study
    Addressing the burdens of neuromyelitis optica spectrum disorder amid challenges of the COVID-19 pandemic: real-world perspectives from patients
    Satralizumab treatment in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: a retrospective case series
    Relapse under the prescription of satralizumab in neuromyelitis optica spectrum disorder: analysis of a Japanese claims database
    Use of immunosuppressive therapy among patients with NMOSD using satralizumab treatment: a study based on Japanese real-world data

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
星期二, 九月 5, 2023
AIM, PD, Event, NMOSD, Parkinson's disease, TSX, Neuromyelitis optica spectrum disorder, Immunosuppression, Conference

TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually.

Key Points: 
  • TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually.
  • Dr. Paulini will provide a corporate overview and will focus his presentation on the Company’s Autoimmunity Modifying (AIM) Biologicals development programs.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Retrieved on: 
星期五, 八月 25, 2023
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Healthcare Reform, Science, Legal, Congressional News, Views, Health, Public Policy, Government, Orphan Drug Act of 1983, Eculizumab, REMS, Central nervous system, Drug development, Vaccination, Prostate cancer, GMG, Infection, Attenuated vaccine, Fever, JAMA, Cancer, Light, Neuromyelitis optica spectrum disorder, Breast, Medicine, NMOSD, IRA, AstraZeneca, Rash, American Medical Association, Neisseria meningitidis, Vomiting, Inflation, ODA, Low-probability-of-intercept radar, Meningococcal vaccine, Patient, Risk, Autoimmune disease, PNH, Immune system, Nausea, Confusion, Inflation Reduction Act of 2022, Rare, Headache, Patient safety, Death, Disease, Pharmaceutical industry, Vaccine

To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).

Key Points: 
  • To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Rare disease and cancer patients depend upon high-risk, low-probability drug development that takes many years to develop and aims for cure.
  • One example is LYNPARZA® (olaparib), a small-molecule cancer medicine approved in 2014 in the US for a small group of late-line ovarian cancer patients.
  • Additional trials added small groups of breast and pancreatic cancer patients, with the most recent indication in prostate cancer approved just this year – nine years later.

Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups

Retrieved on: 
星期三, 八月 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Other Health, Rarey technique, Partnership, Education, NMO, Overalls, NMOSD, Organization, Rare, Patient, Scholarship, Neuromyelitis optica spectrum disorder, Disease, TED, Pharmaceutical industry, Nursing

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company.
  • “We are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,” said Matt Flesch, vice president, patient advocacy and product communications, Horizon.
  • From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.”
    In the PatientView report summarizing survey results from rare disease groups, 91 rare disease patient advocacy groups said they were familiar with Horizon and 59 said they worked with the company.
  • In previous PatientView results released in the first half of 2023 , Horizon ranked second in overall corporate reputation and first in patient centricity and integrity among all patient advocacy groups around the world who worked with the company (not just rare disease groups), and first in overall corporate reputation among patient advocacy groups in the United States.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Retrieved on: 
星期二, 八月 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Maintenance, Ciba-Geigy Canada Ltd v Apotex Inc, Nephrology, Amgen, Policy, Myasthenia gravis, Ophthalmology, Immunomodulation, NMOSD, Patient, IgG4-related disease, Physician, Rheumatology, CAS, Growth, American Association of Clinical Endocrinologists, Neuromyelitis optica spectrum disorder, Pharmaceutical industry, TED

Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.

Key Points: 
  • Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.
  • Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales.
  • The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment.
  • In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results.